© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Patients with polypoidal choroidal vasculopathy may benefit from intravitreal aflibercept.
Patients with polypoidal choroidal vasculopathy may benefit from intravitreal aflibercept (Eylea, Bayer HealthCare). According to a study in Retina, treatment-naïve patients with polypoidal choroidal vasculopathy who received aflibercept demonstrated improved vision at a 6-month follow-up. The therapy was well-tolerated and might also be associated with achieving involution of polyps and reducing exudative findings, according to the researchers.
Sixteen treatment-naïve patients with polypoidal choroidal vasculopathy received intravitreal aflibercept between February 2013 and July 2013.
At 6 months after the initial treatment, a significantly better best-corrected visual acuity was seen, compared with baseline.
In addition:
To read the abstract of the study, click here.